Research Summaries

Mitochondrial Peptides: MOTS-c, SS-31, NAD+, and the Science of Cellular Energy

PepTracker Pro Research Team February 10, 2026 16 min read

Last reviewed: April 17, 2026

Why Mitochondria Matter for Aging
The Electron Transport Chain and Energy Production
MOTS-c: The Exercise Mimetic
MOTS-c Mechanisms and Metabolic Effects
SS-31 (Elamipretide): Protecting the Inner Membrane
SS-31 Clinical Development and Barth Syndrome
NAD+: The Central Coenzyme
NAD+ Decline Kinetics and Aging
NAD+ Precursors and Delivery Technologies
Epithalon: The Telomerase Connection
Telomere Biology and Mitochondrial Aging Connections
Thymalin and the Immune-Aging Axis
Combination Approaches
Current Clinical Trial Landscape
Important Caveats and Realistic Expectations

Why Mitochondria Matter for Aging

Mitochondria are the energy-producing organelles present in nearly every cell (with notable exceptions like mature red blood cells). They convert nutrients (glucose, fatty acids, amino acids) into ATP — the molecular fuel that powers cellular processes from muscle contraction to protein synthesis to neuronal signaling. The mitochondrial electron transport chain (ETC) oxidizes NADH and FADH2 produced during metabolism, using the energy to pump protons across the inner mitochondrial membrane, creating a proton gradient. ATP synthase harnesses this gradient to synthesize ATP from ADP and phosphate. As we age, mitochondrial function declines through multiple mechanisms: ETC efficiency drops, oxidative damage accumulates, mitophagy (autophagy of damaged mitochondria) becomes less efficient, and mtDNA mutations accumulate. This mitochondrial dysfunction is now considered one of the hallmarks of aging (alongside telomere shortening, genomic instability, and others), and targeting it has become a major focus of longevity research.

The Electron Transport Chain and Energy Production

The ETC consists of four protein complexes (I-IV) embedded in the inner mitochondrial membrane, plus ATP synthase (Complex V). Complex I oxidizes NADH, passing electrons through complexes II-IV, ultimately reducing oxygen to water. Each electron transfer releases energy used to pump H+ ions across the membrane. The resulting proton gradient (approximately 1,000:1 concentration difference) drives ATP synthase, which synthesizes roughly 2.5 ATP per NADH oxidized. This is remarkably efficient compared to substrate-level phosphorylation. However, during ETC operation, approximately 1-3% of electrons leak and react with oxygen, generating reactive oxygen species (ROS). These free radicals damage proteins, lipids, and DNA, including mtDNA. ROS accumulation and insufficient antioxidant defenses are hallmarks of aging. Protecting the ETC from damage or enhancing its efficiency is therefore a rational anti-aging strategy.

MOTS-c: The Exercise Mimetic

MOTS-c (mitochondrial open reading frame of the twelve S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial genome itself — making it one of a small number of 'mitochondrial-derived peptides' (MDPs). The mitochondrial genome was thought to encode only proteins; the discovery of MOTS-c challenged this, revealing that cryptic ORFs (open reading frames) encode functional peptides. MOTS-c was discovered in 2015 by the Lee lab at UCLA. In preclinical studies, MOTS-c has been described as an 'exercise mimetic' because it activates AMPK (AMP-activated protein kinase), the same energy-sensing pathway triggered by physical exercise. AMPK acts as a cellular 'energy meter' — activated when ATP/AMP ratio drops, signaling energy deficit. MOTS-c-activated AMPK improves insulin sensitivity, enhances glucose metabolism, reduces inflammation, and increases metabolic flexibility (ability to switch between glucose and fat oxidation). It appears to function as a retrograde signal — mitochondria communicating their energy status to the nucleus — and triggers gene expression changes that enhance mitochondrial biogenesis.

MOTS-c Mechanisms and Metabolic Effects

MOTS-c binds to formyl peptide receptor 2 (FPR2) and other receptors on cell surfaces, triggering AMPK activation. Unlike systemically administered AMPK activators that affect all tissues, MOTS-c appears to have preference for metabolically active tissues (muscle, adipose, liver). In obese rodent models, MOTS-c improves glucose tolerance, decreases hepatic steatosis (fatty liver), and promotes weight loss. In aging models, MOTS-c extends lifespan and improves age-related metabolic decline. These effects occur through multiple pathways: increased mitochondrial biogenesis, enhanced FAO (fatty acid oxidation) capacity, improved insulin signaling, and reduced inflammation. Remarkably, MOTS-c levels decline with age, particularly in men — restoration might reverse age-related metabolic decline.

SS-31 (Elamipretide): Protecting the Inner Membrane

SS-31 (elamipretide) takes a fundamentally different approach from MOTS-c — rather than being produced by mitochondria (like MOTS-c), it is an exogenous synthetic tetrapeptide designed to penetrate mitochondria and protect them. SS-31 selectively binds to cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential for: optimal ETC function (it anchors and stabilizes ETC complexes), formation of respiratory supercomplexes (organized arrangements of ETC proteins that improve efficiency), and prevention of pathological ROS production. In aging and disease, cardiolipin becomes oxidized and degraded, impairing ETC function and increasing ROS generation. SS-31 stabilizes cardiolipin, protecting it from oxidative damage and maintaining ETC integrity.

SS-31 Clinical Development and Barth Syndrome

SS-31 (elamipretide, also known as Bendavia) has progressed further into clinical development than most mitochondrial peptides. It is currently in Phase 2/3 trials for heart failure and Phase 2 trials for age-related mitochondrial dysfunction. Notably, SS-31 received FDA Breakthrough Designation for Barth syndrome — a rare genetic disorder (mutation in TAZ gene) that impairs cardiolipin remodeling, causing cardiomyopathy, skeletal myopathy, and immunodeficiency. SS-31 appears to partially compensate for defective cardiolipin remodeling. Published trials show modest but consistent improvements in cardiac function and exercise capacity in heart failure patients. The evidence base for SS-31 is stronger than most mitochondrial interventions, though benefits are modest rather than dramatic.

NAD+: The Central Coenzyme

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme (not a peptide) that is fundamental to mitochondrial energy production and cellular metabolism broadly. It functions as an electron carrier — accepting electrons during oxidation reactions (becoming NADH) and donating them during reduction reactions (returning to NAD+). NAD+ participates in over 500 enzymatic reactions, including all three stages of cellular respiration. Beyond energy metabolism, NAD+ activates sirtuins (SIRT1-7), a family of proteins with NAD+-dependent deacetylase activity. Sirtuins regulate gene expression, DNA repair, mitochondrial biogenesis, and stress resistance — processes linked to longevity. Studies in yeast, worms, flies, and mice show that NAD+ supplementation or activation extends lifespan and improves age-related phenotypes. NAD+ levels decline significantly with age — approximately 50% reduction by age 60. Restoring NAD+ is therefore a rational anti-aging strategy.

NAD+ Decline Kinetics and Aging

NAD+ declines progressively from young adulthood through old age, with the steepest declines in the sixth and seventh decades. The mechanism: NAD+ is consumed by NAD+-consuming enzymes (sirtuins, PARPs, CD38/CD157 ADP-ribosyl cyclases) and degraded by NAD+ phosphatases. Meanwhile, NAD+ synthesis (through salvage pathways from tryptophan, or salvage of nicotinamide and NMN) becomes less efficient with age. This is partly due to reduced NAD+ salvage enzyme activity (NAMPT — nicotinamide phosphoribosyltransferase — declines with age). The net result: accelerating NAD+ depletion. This depletion impairs mitochondrial ATP production, reduces SIRT1-mediated stress resistance, impairs DNA repair, and likely contributes to age-related pathology. Preclinical studies suggest that blocking NAD+ depletion (through NAD+ supplementation or NAMPT activation) reverses some aging phenotypes.

NAD+ Precursors and Delivery Technologies

Direct NAD+ supplementation faces bioavailability challenges — NAD+ is large, charged, and difficult to absorb orally. Instead, precursors are used: NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), or tryptophan. NMN (256 Da) is converted to NAD+ intracellularly via NMNAT. NR (215 Da) is converted via salvage pathways. Both have better oral bioavailability than NAD+ itself, though still suboptimal. IV NAD+ infusions bypass absorption issues but require medical administration and are expensive. Emerging technologies include: NMN in liposomal or nanoparticle formulations (improving absorption), direct mitochondrial targeting (NAD+ analogs that accumulate in mitochondria), and combination approaches (NMN + NAD+ consuming enzyme inhibitors). Most available data support NMN and NR safety at doses up to 1-2 grams daily, though clinical efficacy data in humans are limited.

Epithalon: The Telomerase Connection

Epithalon (also called epitalon or epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly or AEDG sequence) derived from the natural peptide epithalamin, extracted from the pineal gland. It was developed at the Institute of Gerontology in St. Petersburg, Russia, as part of a broader program exploring bioregulatory peptides for aging. Epithalon has been studied primarily in Russian laboratories for its ability to activate telomerase, the enzyme that adds telomeric repeats to chromosome ends. Telomeres shorten with each cell division — a molecular 'clock' of aging. Telomerase is normally active only in germline cells, stem cells, and some immune cells. Most somatic cells lack telomerase and undergo replicative senescence after 50-70 divisions (Hayflick limit). Epithalon's activation of telomerase in somatic cells is theoretically appealing for anti-aging.

Telomere Biology and Mitochondrial Aging Connections

Telomere shortening and mitochondrial dysfunction are interconnected: cells with critically short telomeres often show impaired mitochondrial function, increased ROS, and senescence. Conversely, mitochondrial dysfunction (from mutations or damage) accelerates telomere shortening through increased ROS. This vicious cycle may amplify aging. Addressing either telomere shortening (epithalon approach) or mitochondrial function (MOTS-c, SS-31 approaches) might interrupt this cycle. However, activating telomerase globally carries cancer risk — unrestricted telomere elongation is a hallmark of cancer cells. Epithalon's effects on cancer risk are unknown. This limits clinical utility of telomerase-activating approaches unless targeted to specific cell types.

Thymalin and the Immune-Aging Axis

Thymalin is a thymic peptide preparation studied alongside epithalon as part of the Russian bioregulatory peptide program. The thymus gland atrophies dramatically with age, producing fewer T-cells. This thymic involution drives immunosenescence — age-related decline in immune function. Thymalin aims to restore thymic function and T-cell production. While seemingly distinct from mitochondrial aging, immune cell function is heavily dependent on mitochondrial fitness. Activated T-cells have dramatically higher ATP demand than resting cells; mitochondrial dysfunction limits immune responses. Age-related immune decline is increasingly understood through the lens of mitochondrial dysfunction in immune cells. Thymalin may work partly by supporting mitochondrial function in thymic epithelial and T-cells.

Combination Approaches

What makes mitochondrial research compelling is how interconnected these pathways are. MOTS-c improves the metabolic environment that mitochondria operate in, reducing ROS production and metabolic stress. SS-31 protects mitochondrial membranes from ROS damage. NAD+ provides the electron carrier and sirtuin fuel essential for mitochondrial biogenesis and stress resistance. Epithalon addresses genomic stability (telomere maintenance) that protects against senescence and cancer risk. No single compound addresses every aspect of mitochondrial aging. Rationally combining compounds with complementary mechanisms might achieve synergistic effects. For example: NMN (restoring NAD+) + SS-31 (protecting ETC) + MOTS-c (activating mitochondrial biogenesis) theoretically addresses multiple aspects of mitochondrial decline. However, formal studies of combination approaches are largely absent.

Current Clinical Trial Landscape

SS-31 is the most advanced, with Phase 2/3 trials ongoing in heart failure and Barth syndrome. MOTS-c recently entered Phase 1 human trials. NAD+ precursors have multiple commercial products (Tru Niagen, Namu, etc.) available over-the-counter, with ongoing clinical trials examining effects on cardiovascular health, neurological disease, and aging phenotypes. Epithalon remains primarily studied in Russian centers with limited English-language literature. Phase 3 human trials are years away for most mitochondrial peptides, and large, well-powered longevity trials are non-existent — proving that a compound extends human lifespan requires decades of follow-up, making such trials impractical.

Important Caveats and Realistic Expectations

The evidence base varies significantly across these compounds. NAD+ precursors have substantial human data supporting their safety and ability to raise NAD+ levels, though clear clinical longevity outcomes are still being studied. SS-31 has been through multiple clinical trials with modest but consistent positive results in specific disease contexts. MOTS-c remains primarily preclinical, with human trials only recently beginning — most human efficacy data are absent. Epithalon's evidence comes largely from a single research group with limited independent replication. All represent exciting science with plausible mechanisms, but none should be considered proven anti-aging interventions at this time. Longevity is a multifactorial trait influenced by genetics, lifestyle, nutrition, and stress — no single peptide will dramatically extend human lifespan. Consult a healthcare provider before considering any of these compounds, especially in combination.

Ready to track your peptide research?

Open PepTracker Pro

PepTracker Pro Research Team

The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.

Citations

[1] Lee C et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis, Cell Metab 2015 Source
[2] Szeto HH — First-in-class cardiolipin-protective compound, Br J Pharmacol 2014 Source
[3] Rajman L et al. — Therapeutic potential of NAD-boosting molecules, Cell Metab 2018 Source
[4] Khavinson VK et al. — Epithalon peptide induces telomerase activity, Bull Exp Biol Med 2003 Source

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer →